skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange

Journal Article · · Nature Communications
DOI:https://doi.org/10.1038/ncomms11610· OSTI ID:1299090

Omalizumab is a widely used therapeutic anti-IgE antibody. Here we report the crystal structure of the omalizumab–Fab in complex with an IgE-Fc fragment. This structure reveals the mechanism of omalizumab-mediated inhibition of IgE interactions with both high- and low-affinity IgE receptors, and explains why omalizumab selectively binds free IgE. The structure of the complex also provides mechanistic insight into a class of disruptive IgE inhibitors that accelerate the dissociation of the high-affinity IgE receptor from IgE. We use this structural data to generate a mutant IgE-Fc fragment that is resistant to omalizumab binding. Treatment with this omalizumab-resistant IgE-Fc fragment, in combination with omalizumab, promotes the exchange of cell-bound full-length IgE with omalizumab-resistant IgE-Fc fragments on human basophils. Furthermore, this combination treatment also blocks basophil activation more efficiently than either agent alone, providing a novel approach to probe regulatory mechanisms underlying IgE hypersensitivity with implications for therapeutic interventions.

Research Organization:
SLAC National Accelerator Laboratory (SLAC), Menlo Park, CA (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
AC02-76SF00515
OSTI ID:
1299090
Journal Information:
Nature Communications, Vol. 7; ISSN 2041-1723
Publisher:
Nature Publishing GroupCopyright Statement
Country of Publication:
United States
Language:
English
Citation Metrics:
Cited by: 64 works
Citation information provided by
Web of Science

References (55)

Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells journal June 2014
Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation journal October 2013
Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI journal April 2011
IgE Enhances Antibody and T Cell Responses In Vivo via CD23 + B Cells journal July 2005
Accelerated disassembly of IgE–receptor complexes by a disruptive macromolecular inhibitor journal October 2012
IgE and mast cells in allergic disease journal May 2012
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma journal February 2014
“Auto-anti-IgE”: Naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation journal December 2014
Soluble CD23 Controls IgE Synthesis and Homeostasis in Human B Cells journal March 2012
Monitoring free serum IgE in severe asthma patients treated with omalizumab journal November 2012
Regulation of Syk kinase and FcRβ expression in human basophils during treatment with omalizumab journal April 2010
IgE in allergy and asthma today journal March 2008
Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma journal October 2006
Regulation of IgE Synthesis by CD23/CD21 Interaction journal January 1995
A single glycan on IgE is indispensable for initiation of anaphylaxis journal March 2015
Omalizumab-induced reductions in mast cell FcεRI expression and function journal September 2004
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma journal August 2001
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma journal July 2009
High affinity targeting of CD23 inhibits IgE synthesis in human B cells. text January 2015
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study journal March 2015
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects journal October 2014
Inference of Macromolecular Assemblies from Crystalline State journal September 2007
UCSF Chimera?A visualization system for exploratory research and analysis journal January 2004
Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis journal October 2012
Conformational Flexibility in Immunoglobulin E-Fc3–4 Revealed in Multiple Crystal Forms journal October 2009
The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma journal August 2013
Structure of the Human IgE-Fc Cε3-Cε4 Reveals Conformational Flexibility in the Antibody Effector Domains journal September 2000
CD21 is a ligand for CD23 and regulates IgE production journal August 1992
Negative feedback regulation of IgE synthesis by murine CD23 journal June 1994
Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy journal February 2012
A time-resolved fluorescence resonance energy transfer assay suitable for high-throughput screening for inhibitors of immunoglobulin E–receptor interactions journal December 2012
PHENIX: a comprehensive Python-based system for macromolecular structure solution journal January 2010
Role of Glycosylation Sites in the IgE Fc Molecule journal January 1995
Omalizumab treatment downregulates dendritic cell FcεRI expression journal December 2003
Antibody neutralization and escape by HIV-1 journal March 2003
In vivo enhancement of the specific antibody response via the low-affinity receptor for IgE journal July 1993
Facilitated dissociation of IgE versus cell replacement journal January 2015
Structural and Physical Basis for Anti-IgE Therapy journal June 2015
The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update: The ‘hygiene hypothesis’: an update journal March 2010
PHENIX: a comprehensive Python-based system for macromolecular structure solution. text January 2010
Coot model-building tools for molecular graphics journal November 2004
Perivascular Mast Cells Dynamically Probe Cutaneous Blood Vessels to Capture Immunoglobulin E journal January 2013
An Unusual Mechanism for Ligand Antagonism journal July 1998
Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc RI journal July 2012
DARPins against a functional IgE epitope journal October 2010
Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors journal November 2012
High affinity targeting of CD23 inhibits IgE synthesis in human B cells: High affinity targeting of CD23 journal July 2015
Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα journal July 2000
Structure of the omalizumab Fab journal March 2015
An Engineered Disulfide Bond Reversibly Traps the IgE-Fc 3–4 in a Closed, Nonreceptor Binding Conformation journal September 2012
Characterization of truncated alpha chain products from human, rat, and mouse high affinity receptor for immunoglobulin E journal February 1991
A monoclonal anti-IgE antibody against an epitope (amino acids 367-376) in the CH3 domain inhibits IgE binding to the low affinity IgE receptor (CD23). journal November 1988
Binding the low affinity Fc epsilon R on B cells suppresses ongoing human IgE synthesis. journal January 1989
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. journal February 1997
The binding site on human immunoglobulin E for its high affinity receptor journal October 1994

Cited By (17)

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab journal April 2017
The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses journal November 2018
Food allergy: immune mechanisms, diagnosis and immunotherapy journal October 2016
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. text January 2020
Component analysis and antiasthmatic effects of Huashanshen dripping pill journal November 2019
The role of CD23 in the regulation of allergic responses journal January 2021
Controlling Mast Cell Activation and Homeostasis: Work Influenced by Bill Paul That Continues Today journal April 2018
Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody journal August 2018
From IgE to Omalizumab journal November 2016
IL-3 but not monomeric IgE regulates FcεRI levels and cell survival in primary human basophils journal May 2018
Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria journal February 2020
Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc RI journal July 2012
Approaches to target IgE antibodies in allergic diseases journal November 2018
Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools journal April 2019
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab journal January 2020
Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses journal January 2019
All the small things: How virus‐like particles and liposomes modulate allergic immune responses journal November 2019